Observational Study on Circulating Tumor DNA for Early Cancer Response
This study is looking at how circulating tumor DNA (ctDNA) can help detect cancer recurrence earlier in people with prostate, head and neck, esophageal, or genitourinary cancers, as well as healthy volunteers. ctDNA is tiny pieces of tumor DNA found in the blood. The study aims to see if earlier detection of cancer recurrence through ctDNA can lead to better treatment options and improved patient outcomes. Success in this study will be measured by how long participants remain free from cancer progression. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study planning to enroll 100 participants. It is not testing a specific intervention or drug.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for freedom from progression through the completion of the study, estimated to be 6.5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Melissa Reimers, M.D. · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Freedom from progressionThrough completion of study (estimated to be 6.5 years)
-Defined as RECIST 1.1 based radiographic or clinical progression, with non-progressors censored at last radiographic follow-up